Insider filing · TVTX
Sandra Calvin
SVP, CHIEF ACCOUNTING OFFICER
profile →
Travere Therapeutics, Inc.
TVTX · Healthcare · 74 filings in 24 months
ticker →
Sandra Calvin sold $266K of Travere Therapeutics (TVTX)
Executed Sep 15, disclosed Sep 18, 2 days later.
Value, as filed
$266K
4,275 sh × $62.13
Executed
Sep 15
the trade date, as filed
Disclosed
Sep 18
2 days after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
SCSandra Calvin (SVP, CHIEF ACCOUNTING OFFICER) filed 6 Form 4 reports in the trailing twelve months (0 purchases, 6 sales), most often in Travere Therapeutics, Inc. (TVTX). The largest single filing was $2.4M of TVTX (67,115 sh × $36.00, as filed), executed Nov 4 2025.
The name
TVTXHealthcare · Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by Sandra Calvin in TVTX
TVTXSALE
Travere Therapeutics, Inc.
$903K21,977 sh × $41.07
Exec Apr 14
Filed Apr 16 · 5:30 PM ET TVTXSALE Travere Therapeutics, Inc. $139K
4,333 sh × $32.12
Exec Feb 3
Filed Feb 3 · 5:30 PM ET TVTXSALE Travere Therapeutics, Inc. $296K
7,402 sh × $40.00
Exec Dec 24 2025
Filed Dec 29 2025 · 5:30 PM ET TVTXSALE Travere Therapeutics, Inc. $105K
2,910 sh × $36.00
Exec Dec 15 2025
Filed Dec 16 2025 · 5:30 PM ET TVTXSALE Travere Therapeutics, Inc. $2.4M
67,115 sh × $36.00
Exec Nov 4 2025
Filed Nov 6 2025 · 5:30 PM ET TVTXSALE Travere Therapeutics, Inc. $1.4M
54,244 sh across 5 lots
Exec Feb 11 2025
Filed Feb 12 2025 · 5:30 PM ET TVTXSALE Travere Therapeutics, Inc. $258K
15,000 sh × $17.22
Exec Dec 26 2024
Filed Dec 27 2024 · 5:30 PM ET TVTXSALE Travere Therapeutics, Inc. $221K
12,090 sh × $18.30
Exec Nov 25 2024
Filed Nov 25 2024 · 5:30 PM ET